1Nathan DM, Buse JB, Davidson MB, et at. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetologia, 2009, 52: 17-30.
2Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association(ADA) and the European Association for the Study of Diabetes(EASD)[J]. Diabetes Care, 2012, 35(6): 1364-1379.
3Garber AJ, Abrahamson M J, Barzilay JI, et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement executive summary[J]. Endocr Pract, 2013, 19(3): 536-557.
5Kolterman OG, Kim DD, Shen L, et al. Pharmacokineties, pharmacodynamies, and safety of exenatide in patients with type 2 diabetes mellitus[J]. Am J Health Syst Pharm, 2005, 62(2): 173- 1 81.
6Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon- like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus[J]. Endocrinol Metab, 2013, 28: 262-274.
7Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[J]. Mol Cell Endocrinol, 2009, 297(1-2): 137-140.
8DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide)microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes[J]. Diabetes Technol Ther, 2011, 13(11): 1145-1154.
9Mann KV, Raskin P. Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes[J]. Diabetes Metab Syndr Obes, 2014, 7: 229-239.
10Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006, 368(9548): 1696-1705.
